Analysis
Top Rated Most Active Strong Potential Positive Momentum Strong Earnings
Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
2.53
2.99
2.95
2.61
Upgraded on attractively valued
Trading below its fair value
Arbutus Biopharma (ABUS) has Medium Risk Level
Click here to check what is your level of risk
Earnings
×Earnings
Reported a weak earnings
Above analyst estimates
Rating
×Rating
Upgraded on attractively valued
Momentum
×Momentum
Price value has negative momentum
Activity
×Activity
Future
×Future
Trading below its fair value
Analysts opinion is positive and also has improved from the past 3 months
Street view is bullish and have positive views on the near-term outlook
Tue May 9, 2023
Tue May 9, 2023
Fri May 5, 2023
Thu May 4, 2023
Tue Apr 25, 2023
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Receive our daily ABUS alerts
Enter your email to receive daily alerts
Leading Gainers
Upgrades
Downgrades
Top Leaders
Ipo's
Dividend
Option Activity
Insiders Activity
Institutional Holdings
New Products
FDA Approvals
Agreements
Financial Reports
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Join the Elite group of subscribers and enjoy exclusive access to more comprehensive and detailed information.
By subscribing, you will gain access to exclusive features that will help you make better decisions and and Level Up your Skills.
Most Trending
Summary
Login to display Arbutus Biopharma (ABUS) recommendation from the last 90 days from financial news and social media.
Strengths
Upgraded on attractively valued
Trading below its fair value
Street view is bullish and have positive views on the near-term outlook
Earnings
×Earnings
Reported a weak earnings
Above analyst estimates
Rating
×Rating
Upgraded on attractively valued
Momentum
×Momentum
Price value has negative momentum
Activity
×Activity
Future
×Future
Trading below its fair value
Analysts opinion is positive and also has improved from the past 3 months
Events Calendar
Hover for information
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Receive our daily ABUS Alerts
Enter your email to receive daily alerts
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Top Headlines
Thu May 18, 2023
Tue Apr 25, 2023
Tue Apr 25, 2023